No Picture
News

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

– Disease control observed in 92% of patients- Conference call to be held today at 2:30pm PT

SAN DIEGO, Nov. 11, 2020 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced updated … […]

No Picture
News

New case study shows virtual reality tools could save biopharmaceutical companies tens of thousands per year

SAN DIEGO, Nov. 2, 2020 /PRNewswire/ — In a case study released October 23 by Oculus for Business from Facebook, Nimbus Therapeutics explains why they expect to save tens of thousands of dollars per year by investing in virtual reality (VR) hardwar… […]

No Picture
News

Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance

— Trial on track to meet prespecified criteria for success on its primary endpoint, with 31% (8/26) disease control rate in evaluable patients in cohorts A and B. Patients eligible for the trial have two consecutive rises in PSA levels indicating init… […]

No Picture
News

Neurelis Announces Four Poster Presentations For The Joint Meeting Of The International Child Neurology Association And Child Neurology Society

– Data continue to support the unique clinical attributes for Neurelis’ lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in pediatric patients 6 years of age and older, adolescents, and … […]

No Picture
News

HUYA Bioscience International Submits HBI-8000 Monotherapy for Adult T-cell Leukemia/Lymphoma for Regulatory Approval in Japan

SAN DIEGO, Oct. 6, 2020 /PRNewswire/ — HUYA Bioscience International (HUYABIOTM ), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the submission of a regulatory application to the Japanese Pharm… […]

No Picture
News

Heron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery

– Over 90% of Hernia Repair Patients Receiving HTX-011 Required No Opioids to Manage Their Postoperative Pain Through 72 hours After Surgery –

SAN DIEGO, Sept. 16, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biote… […]

No Picture
News

Heron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery

– Over 90% of Hernia Repair Patients Receiving HTX-011 Required No Opioids to Manage Their Postoperative Pain Through 72 hours After Surgery –

SAN DIEGO, Sept. 16, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biote… […]

No Picture
News

Puradigm, LLC announces successful tests of its proactive air and surface purification technology in deactivating SARS-CoV-2, the virus that causes COVID-19, as well as deactivating coronavirus 229E

Results from a study done by the University of Florida using the SARS-CoV-2 virus show a significant decrease in infectivity of the virus immediately after exposure to Puradigm’s technology and show the virus was undetectable after 24 hours of expos… […]

No Picture
News

Evofem Biosciences’ CEO Saundra Pelletier Named to PharmaVOICE100 – The Most Inspiring People in Life Sciences

SAN DIEGO, Aug. 3, 2020 /PRNewswire/ — Evofem Biosciences, Inc. (NASDAQ: EVFM) is proud to announce that CEO Saundra Pelletier was named to the PharmaVOICE 100 Most Inspiring People, an annual list of the 100 most innovative, influential and inspir… […]